See more : Viaplay Group AB (publ) (NENT-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Arvinas, Inc. (ARVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arvinas, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Goodricke Group Limited (GOODRICKE.BO) Income Statement Analysis – Financial Results
- Ling Yue Services Group Limited (2165.HK) Income Statement Analysis – Financial Results
- eGain Corporation (EGAN) Income Statement Analysis – Financial Results
- Quebecor Inc. (QBCRF) Income Statement Analysis – Financial Results
- Mahindra & Mahindra Financial Services Limited (M&MFIN.NS) Income Statement Analysis – Financial Results
Arvinas, Inc. (ARVN)
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 78.50M | 131.40M | 46.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Cost of Revenue | 0.00 | 8.20M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 78.50M | 123.20M | 40.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Gross Profit Ratio | 100.00% | 93.76% | 87.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 379.70M | 315.00M | 180.40M | 108.36M | 67.19M | 45.19M | 28.79M | 19.94M |
| General & Administrative | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Other Expenses | 0.00 | 200.00K | 2.50M | 2.00M | 1.44M | 102.73K | 554.16K | 1.66M |
| Operating Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Cost & Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Interest Income | 38.80M | 12.20M | 4.30M | 5.53M | 5.91M | 2.32M | 201.39K | 427.77K |
| Interest Expense | 0.00 | 12.00M | 100.00K | 65.00K | 85.57K | 57.44K | 50.36K | 67.40K |
| Depreciation & Amortization | 6.70M | 8.20M | 6.00M | 4.02M | 2.25M | 706.00K | 347.40K | 436.33K |
| EBITDA | -394.80M | -256.90M | -183.60M | -117.60M | -67.95M | -40.72M | -23.65M | -13.93M |
| EBITDA Ratio | -502.93% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -312.15% | -209.16% |
| Operating Income | -401.50M | -263.20M | -195.30M | -124.86M | -51.52M | -43.80M | -24.76M | -16.47M |
| Operating Income Ratio | -511.46% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -326.70% | -246.95% |
| Total Other Income/Expenses | 37.60M | 12.20M | -2.60M | 1.50M | -18.79M | 2.32M | 711.06K | 2.03M |
| Income Before Tax | -363.90M | -251.00M | -191.00M | -119.33M | -70.29M | -41.48M | -24.05M | -14.44M |
| Income Before Tax Ratio | -463.57% | -191.02% | -408.99% | -547.35% | -163.56% | -289.59% | -317.32% | -216.49% |
| Income Tax Expense | 900.00K | 20.90M | -7.80M | -7.55M | -8.16M | 2.38M | 604.52K | -87.41K |
| Net Income | -367.30M | -271.90M | -183.20M | -111.79M | -62.13M | -41.48M | -24.05M | -14.35M |
| Net Income Ratio | -467.90% | -206.93% | -392.29% | -512.74% | -144.57% | -289.59% | -317.32% | -215.18% |
| EPS | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| EPS Diluted | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| Weighted Avg Shares Out | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
| Weighted Avg Shares Out (Dil) | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Arvinas inks over $1.0 billion deal with Novartis
Arvinas inks over $1.0 billion deal with Novartis
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Arvinas to Participate in Upcoming Investor Conferences
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
Source: https://incomestatements.info
Category: Stock Reports